Kwangdong Healthbio Co., Ltd.

086220KONEXFood products

Kwangdong Healthbio Co., Ltd. (086220, KONEX) reported KRW 67bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202380315718Separate
202466-1-25316Separate
2025671-16218Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20233.3%0.7%31.7%3.2%
2024-1.5%-3%30.1%-12.3%
20251.3%-1%29.4%-3.5%

Revenue moved -16.4% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 11bn
Close priceKRW 898
Listed shares12,687,865
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)218
Women114 (52.3%)
Average tenure5.2 years
Annual pay, menKRW 46,000,000
Annual pay, womenKRW 34,000,000
Pay ratio, women to men73.9%

Other companies in Food products

73 listed companies file under this classification. Showing 12.

See the whole Food products list →